Gyros Protein Technologies
  • IMMUNOASSAY SOLUTIONS
  • PEPTIDE SYNTHESIZERS
  • CORPORATE
  • Interests
    • COVID-19
    • Immunoassays
    • Cell & Gene Therapy
    • Vaccines
  • Products
    • Gyrolab Systems
      • Gyrolab xPlore
      • Gyrolab xPand
    • Gyrolab CDs
    • Gyrolab Kits
    • Gyrolab Software
    • Consumables
    • Service and Support
    • Gyrolab Assay Protocols
  • Applications
    • Pre-clinical
      • Pharmacokinetics (PK)/Toxicokinetics (TK)
      • Biomarker Monitoring & Pharmacodynamics (PD)
      • Affinity
      • Immunogenicity
    • Clinical
      • Pharmacokinetics (PK)/Toxicokinetics (TK)
      • Biomarker Monitoring & Pharmacodynamics (PD)
      • Affinity
      • Immunogenicity
    • Bioprocess
      • Impurity Testing
      • Product Titer Quantification
      • Affinity
  • Resources
    • Gyrolab User Zone
    • SpinBlog
    • Gyrolab Assay Protocols
    • References
    • Brochures
    • Product Information Sheets
    • Application Notes
    • Application Reports
    • Case Studies
    • Posters
    • Seminars
    • Webinars
    • White Papers
    • Certificate of Analysis
    • Instructions for Use
    • MSDS
  • About Us
    • Why Gyrolab
    • Technology
    • Installations Worldwide
    • CRO Partners
    • History
    • News
  • Contact
    • Sales and Support by Region
    • Ordering Information
    • Order Placement
    • Terms & Conditions
Share
  • Share on Facebook
  • Tweet
  • Share on Google+
  • Share on LinkedIn
  • Send email
Subscribe

Gyrolab Spin Blog

Mar 3, 2016 10:59:00 AM

Find the flow and solve matrix interference problems

  • Tweet

Gyros’ technology overcomes matrix effects in a Phase III PK assay

case_study2016.pngIt is not unusual for a pharmacokinetics assay used early on in a study proves to lack the robustness needed to see the drug candidate through to more advanced clinical studies. A team at Genentech experienced just that and they solved the problem by transferring their ELISA to the Gyrolab platform.

 

Read More
0 Comments Click here to read/write comments

Topics: Matrix, Pharmacokinetics, Gyros


All posts

Recent Posts

Related Topic

  • Pharmacokinetics (15)
  • Assay Development (12)
  • Immunoassay (8)
  • Microsampling (8)
  • ADA (5)
  • Assay Automation (5)
  • Matrix (5)
  • Vaccine (5)
  • Gyrolab system (4)
  • Regulated bioanalysis (4)
  • Serial sampling (4)
  • Affinity (3)
  • Biomarkers (3)
  • Bioprocess (3)
  • Gene therapy (3)
  • HCP (3)
  • Toxicokinetics (3)
  • ADME (2)
  • Antibody-Drug Conjugate (2)
  • Clinical trial (2)
  • Immunogenicity (2)
  • Impurity testing (2)
  • Affinity in solution (1)
  • Biodistribution (1)
  • Biosimilars (1)
  • CRO transfer (1)
  • Crohn's disease (1)
  • Diabetes (1)
  • Diabetes biomarkers (1)
  • GLP-1 (1)
  • Gyrolab xPand (1)
  • Gyros (1)
  • Host Cell Proteins (1)
  • Multiplexing (1)
  • Obesity (1)
  • Phase III studies (1)
  • Preclinical studies (1)
  • Symphony peptide synthesizer (1)
  • Toxicology assays (1)
  • Ulcerative colitis (1)
  • solid-phase peptide synthesis (1)
see all
Peptide-synthesizers.png

Get in touch

+46 18 566 300

 

Newsletter sign up!

FacebookLinkedin
  • gyrosproteintechnologies.com
  • Site Use Terms
  • Privacy Policy
  • Legal Notice
Copyright © 2021 Gyros Protein Technologies AB All Rights Reserved.